Antidepressant News and Research

RSS

Antidepressants are medicines that treat depression. Your doctor can prescribe them for you. They can improve your mood, sleep, appetite and concentration. It may take several weeks for them to help. There are several types of antidepressants. You and your doctor may have to try several before finding what works best for you.

Larger hippocampal volume linked with recovery of PTSD

The hippocampus, a brain region implicated in memory and interpreting environmental contexts, has been the focus of a controversy in posttraumatic stress disorder.

22 Mar 2011

Tai chi helps manage depression in older adults

The numbers are, well, depressing: More than 2 million people age 65 and older suffer from depression, including 50 percent of those living in nursing homes. The suicide rate among white men over 85 is the highest in the country - six times the national rate.

17 Mar 2011

Euthymics Bioscience initiates EB-1010 phase 2b/3a TRIADE clinical trial for major depressive disorder

Euthymics Bioscience, Inc. today announced the initiation of an advanced clinical study of its lead product candidate EB-1010 for the treatment of major depressive disorder (MDD). The TRIADE (Triple Reuptake Inhibitor Anti-Depressant Effects) trial is a phase 2b/3a clinical trial designed to assess the safety and efficacy of EB-1010, a novel serotonin-preferring triple reuptake inhibitor.

14 Mar 2011

Supernus SPN-812 Phase IIa U.S. clinical trial in ADHD meets primary endpoints

Supernus Pharmaceuticals, Inc. today announced that its Phase IIa U.S. clinical trial of SPN-812 in adults for the treatment of attention deficit hyperactivity disorder (ADHD) met the primary endpoints of safety and tolerability, and showed statistically significant median reduction versus placebo in both investigator-rated and patient-rated ADHD symptom scores.

11 Mar 2011

MHQP reports significant differences in quality of care delivered by Massachusetts medical groups

Massachusetts Health Quality Partners announced today that despite improvement, there are significant differences in the quality of care delivered by medical groups in Massachusetts, according to its annual Quality Insights: Clinical Quality in Primary Care report.

9 Mar 2011

Prolonged exposure to antidepressants can induce tardive dysphoria

In the current issue of Psychotherapy and Psychosomatics a new important side effect of antidepressant drugs is described: tardive dysphoria.

9 Mar 2011

Patients with epilepsy-linked memory loss worry more than their physicians

Patients with epilepsy worry more than their physicians do about the patients' potential memory loss accompanying their seizure disorder, according to a recent study.

9 Mar 2011

Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder

Neuralstem, Inc. announced that the first subject was dosed yesterday in a Phase Ia trial to evaluate the safety of its drug, NSI-189, which is being developed for the treatment of major depressive disorder and other psychiatric indications. NSI-189 is the lead compound in Neuralstem's neurogenerative small molecule drug platform. This phase of the trial is in healthy volunteers and seeks to determine the maximum tolerated single dose.

2 Mar 2011

Preliminary top-line results from cariprazine 8-week Phase II trial against major depressive disorder

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced preliminary top-line results from an 8-week Phase II clinical trial of the novel, investigational antipsychotic agent cariprazine as adjunctive therapy in major depressive disorder.

28 Feb 2011

Role of serotonin in autism spectrum disorders

Mouse models are yielding important clues about the nature of autism spectrum disorders, which impact an estimated one in 110 children in the U.S. In labs at the UT Health Science Center San Antonio, researchers are studying strains of mice that inherently mimic the repetitive and socially impaired behaviors present in these disorders.

25 Feb 2011

Forest Labs enters definitive merger agreement to acquire Clinical Data

Forest Laboratories, Inc. and Clinical Data, Inc. today announced that they have entered into a definitive merger agreement pursuant to which Forest will acquire Clinical Data, a specialty pharmaceutical company focused on the development of first-in-class and best-in-category therapeutics, for $30.00 per share in cash plus contingent consideration of up to $6.00 per share that may be paid upon achievement of certain commercial milestones related to Viibryd.

22 Feb 2011

Mouse model could help develop new classes of antidepressant drugs

The most widely prescribed antidepressants - medicines such as Prozac, Lexapro and Paxil - work by blocking the serotonin transporter, a brain protein that normally clears away the mood-regulating chemical serotonin. Or so the current thinking goes.

21 Feb 2011

Researchers use computers to capture chemical signal structure that triggers metastatic cancer

In cancer and other pathological diseases, researchers are discovering that packaging is important: specifically, how DNA - about two meters long when unwound and stretched - coils up and compacts neatly inside the nucleus of a cell.

15 Feb 2011

L-methylfolate in combination with antidepressant drug helps major depressive disorder patients

Data published in the January issue of Innovations in Clinical Neuroscience, www.psychiatrymmc.com, suggest when L-methylfolate, a medical food available commercially as Deplin®, and by prescription, is used for dietary management of depression in combination with an antidepressant drug at the start of depression therapy, it results in significantly more patients experiencing major improvement and more rapid improvement than antidepressant monotherapy alone.

10 Feb 2011

Clinical Data reports $2.0 million revenue for third quarter 2011

Clinical Data, Inc. today announced operational and financial results for the third fiscal quarter ended December 31, 2010. The Company received approval from the U.S. Food and Drug Administration (FDA) of Viibryd™ for the treatment of adults with major depressive disorder (MDD) on January 21, 2011.

9 Feb 2011

TREK1 activity offers a key target for fluoxetine and other antidepressant drugs

Using a unique and relatively simple cell-based fluorescent assay they developed, scientists with the U.S. Department of Energy's Lawrence Berkeley National Laboratory and the University of California, Berkeley have identified a means by which fluoxetine, the active ingredient in Prozac, suppresses the activity of the TREK1 potassium channel.

8 Feb 2011

AstraZeneca, Targacept commence TC-5214 Phase 2b clinical trial for major depressive disorder

AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.

7 Feb 2011

Positive results from EpiCept NP-1 Phase IIb trial in patients with CPN

EpiCept Corporation today announced positive results from a Phase IIb trial evaluating the efficacy and safety of EpiCept NP-1 in chemotherapy-induced peripheral neuropathy. EpiCept NP-1 is a topical analgesic cream containing two FDA-approved drugs, amitriptyline and ketamine, in development for the relief of pain from various peripheral neuropathies.

7 Feb 2011

Cognitive behavioral therapy more effective than antidepressant medications for bulimia nervosa

A new evidence report by ECRI Institute comparing the effectiveness of various treatments for bulimia nervosa indicates that cognitive behavioral therapy is more effective than antidepressant medications and supportive therapies in improving eating disorder symptoms.

2 Feb 2011

FDA, Optivia collaborate to examine effect of dietary supplements in drug-induced liver injury

Optivia Biotechnology, a leading provider of in vitro transporter assay services, today announced that the company and the U.S. Food and Drug Administration have signed a collaboration agreement to assess the effect of dietary supplements on key drug transporters.

1 Feb 2011

Antidepressant News and Research

Further Reading

Larger hippocampal volume linked with recovery of PTSD

Tai chi helps manage depression in older adults

Euthymics Bioscience initiates EB-1010 phase 2b/3a TRIADE clinical trial for major depressive disorder

Supernus SPN-812 Phase IIa U.S. clinical trial in ADHD meets primary endpoints

MHQP reports significant differences in quality of care delivered by Massachusetts medical groups

Prolonged exposure to antidepressants can induce tardive dysphoria

Patients with epilepsy-linked memory loss worry more than their physicians

Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder

Preliminary top-line results from cariprazine 8-week Phase II trial against major depressive disorder

Role of serotonin in autism spectrum disorders

Forest Labs enters definitive merger agreement to acquire Clinical Data

Mouse model could help develop new classes of antidepressant drugs

Researchers use computers to capture chemical signal structure that triggers metastatic cancer

L-methylfolate in combination with antidepressant drug helps major depressive disorder patients

Clinical Data reports $2.0 million revenue for third quarter 2011

TREK1 activity offers a key target for fluoxetine and other antidepressant drugs

AstraZeneca, Targacept commence TC-5214 Phase 2b clinical trial for major depressive disorder

Positive results from EpiCept NP-1 Phase IIb trial in patients with CPN

Cognitive behavioral therapy more effective than antidepressant medications for bulimia nervosa

FDA, Optivia collaborate to examine effect of dietary supplements in drug-induced liver injury

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News